KR920700691A - Wound, incision, the use of liposomes (liposomes) for the administration of the therapeutic agent to the abrasion site - Google Patents

Wound, incision, the use of liposomes (liposomes) for the administration of the therapeutic agent to the abrasion site

Info

Publication number
KR920700691A
KR920700691A KR1019910701279A KR910701279A KR920700691A KR 920700691 A KR920700691 A KR 920700691A KR 1019910701279 A KR1019910701279 A KR 1019910701279A KR 910701279 A KR910701279 A KR 910701279A KR 920700691 A KR920700691 A KR 920700691A
Authority
KR
South Korea
Prior art keywords
method
characterized
liposomes
mol
polymer
Prior art date
Application number
KR1019910701279A
Other languages
Korean (ko)
Inventor
미첼 쇼 잭
마리아 코르도바 다이아나
Original Assignee
존.에프.맥인티리
알콘 레보레이토리 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33316489A priority Critical
Priority to US333164 priority
Application filed by 존.에프.맥인티리, 알콘 레보레이토리 인코오포레이티드 filed Critical 존.에프.맥인티리
Priority to PCT/US1990/001664 priority patent/WO1990011781A1/en
Publication of KR920700691A publication Critical patent/KR920700691A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes

Abstract

내용 없음 No information

Description

상처부위, 절개부위, 찰과상 부위에 치료제의 투여에 대한 리포좀(LIPOSOMES)의 용도 Wound, incision, the use of liposomes (LIPOSOMES) for the administration of the therapeutic agent to the abrasion site

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음 This information did not disclose more professional information because lumbar Articles

도면은 각막 상처에 본 발명의 리포좀 흡착 대 비상처 각막에 리포좀의 상대적인 비흡착을 도시한 것이다. The figure shows a relative ratio of the liposome adsorbed on the liposomes versus non-adsorbed corneal wounds of the present invention on corneal wound.

Claims (28)

  1. 상처에 흡착되는 리포좀내에 치료제의 효과적인 양을 함유하는 조성물을 감염된 눈에 국소적 적용하는 것으로 구성되어 치료를 위한 눈의 상처를 치료하는 방법. A method for treating a wound in the eye for the treatment consists in applying topically to the affected eye a composition containing an effective amount of a therapeutic agent into the liposomes are adsorbed to a wound.
  2. 제1항에 있어서, 상기 리포좀은 합성 또는 천연적으로 발생하는 인지질 약 50~90몰% 및 콜레스테롤 약10~50몰% 구성되는 것을 특징으로 하는 방법. The method of claim 1, wherein the liposome is characterized in that the phospholipid composed of about 50 to 90 mol% cholesterol and 10 to 50 mol% of a synthetic or naturally occurring.
  3. 제2항에 있어서, 상기 인지질은 14 내지 18개의 탄소의 아실 사슬을 가지며, 상기 사슬은 포화되거나 또는 하나의 불포화 결합을 함유하는 포스파티딜콜린, 포스파티딜세롤, 포스타티딜에탄올 및 포스파티딜세린을 구성하는 기로부터 선택된 것임을 특징으로 하는 방법. The method of claim 2, wherein the phospholipid is from 14 to having a 18-acyl chain of carbons, wherein the chain is saturated or is selected from the group constituting one unsaturated phosphatidylcholine, phosphatidyl glycerol, poster peptidyl ethanol and phosphatidylserine containing bond characterized in that.
  4. 제2항에 있어서, 상기 리포좀은 포스파티딜콜린 50몰%, 포스파티딜글리세롤 30몰% 및 콜레스테롤 20몰%로 구성되는 것을 특징으로하는 방법. The method of claim 2 wherein the liposome is characterized in that consisting of phosphatidylcholine 50 mol% and 30 mol% phosphatidylglycerol and cholesterol 20 mol%.
  5. 제4항에 있어서, 상기 리포좀의 직경이 약 10 내지 10,000nm임을 특징으로 하는 방법. According to claim 4, characterized in that the diameter of the liposomes from about 10 to 10,000nm.
  6. 제1항에 있어서, 상기 리포좀의 직경이 약 10 내지 10,000nm 임을 특징으로 하는 방법. The method of claim 1, characterized in that the diameter of the liposomes from about 10 to 10,000nm.
  7. 제6항에 있어서, 상기 리포좀의 직경이 약 20 내지 500nm임을 특징으로 하는 방법. 7. The method of claim 6, characterized in that the diameter of the liposomes of about 20 to 500nm.
  8. 제1항에 있어서, 상기 중합체는 약 5cps와 1000cps 사이의 점도를 갖는 조성물 제공하기 위하여 충분한 양의 중합체를 구성하는 것을 특징으로 하는 방법. The method of claim 1 wherein said polymer is characterized in that constituting a sufficient amount of polymer to provide a composition having a viscosity of between about 5cps and 1000cps.
  9. 제8항에 있어서, 상기 리포좀은 합성 또는 천연적으로 발생하는 인지질 50~90몰% 및 콜레스테롤 10~50몰%으로 구성되고, 상기 중합체 농도가 약 0.25~3.0중량%인 것을 특징으로 하는 방법. 9. The method of claim 8 wherein the liposomes method of synthesis, or consists of a naturally occurring phospholipids from 50 to 90 mol% and cholesterol 10 to 50 mol% occurring, characterized in that the polymer concentration is about 0.25 ~ 3.0 wt%.
  10. 제8항에 있어서, 상기 중합체는 다당류, 겔라틴, 알부민, 카세인, 치토산, 콜라겐, 폴리락티드, 폴리락티드글리코라이드, 코폴이머, 폴리오르소에스터, 폴리메타크릴레이트, 폴리비닐알콜, 폴리아크릴 릭산, 폴리비닐피를리돈, 폴리하이드록시에틸메타크릴레이트, 폴리에스터아미드, 폴리에틸렌글리콜 및 롤리머릭 아미노산을 구성하는 기로부터 선택되는 것을 특징으로 하는 방법. 9. The method of claim 8 wherein the polymer is a polysaccharide, gelatin, albumin, casein, values ​​acid, collagen, polylactide, polylactide glycolic fluoride, kopol timer, poly ortho esters, polymethacrylate, polyvinyl alcohol, characterized in that the polyacrylic acid, selected from the group of the polyvinyl pyrrolidone, poly-hydroxy configuration the hydroxyethyl methacrylate, polyester, polyamide, polyethylene glycol, and Raleigh numeric amino acid.
  11. 제10항에 있어서, 상기 중합체가 겔라틴임을 특징으로 하는 방법. 11. The method of claim 10, characterized in that the polymer is gelatin.
  12. 상처의 치료를 증진하기 위하여, 흡착의 수단에 의해 상처에 선택적인 결합을 위해 적용된 리포좀내 함유되는 충분한 약제의 양의 제약의 조성물을 상처에 국소적 적용하는 것으로 구성되어 상처의 치료를 증진하기 위하여 외과 수술의 눈의 상처를 치료하기 위한 방법. In order to promote the treatment of wounds, it consists in the topical application to the amount of the composition hurt the constraints of sufficient drug to be contained within liposomes is applied for selective coupling to the wound by means of suction in order to promote the treatment of wounds how to treat the wounds of surgical eye.
  13. 제12항에 있어서, 상기 리포좀은 합성 또는 천연적으로 발생하는 인지질 약 50-90몰%및 콜레스테롤 약 10~50몰%로 구성되는 것을 특징으로 하는 방법. The method of claim 12, wherein the liposome is characterized in that is composed of about 50-90 mole% of a phospholipid that occurs naturally or synthetically and cholesterol about 10 to 50 mol%.
  14. 제13항에 있어서, 상기 인지질은 14내지 18개의 탄소의 아실 사슬을 가지며, 상기 사슬은 포화되거나 또는 하나의 불포화 결합을 함유하는 포스파티딜콜린, 포스파티글리세롤, 포그타티딜에탄올아민 및 포스파티딜세린을 구성하는 기로부터 선택된 것임을 특징으로 하는 방법. The method of claim 13 wherein the phospholipid is 14 has a to 18 acyl chain of carbons, wherein the chain is a saturated or constitutes a phosphatidylcholine containing an unsaturated bond, a phosphatide glycerol, fog Tatiana dill ethanolamine and phosphatidylserine characterized in that from the selected group.
  15. 제12항에 있어서, 상기 리포좀의 직경이 약 10 내지 10,000nm임을 특징으로 하는 방법. 13. The method of claim 12, characterized in that the diameter of the liposomes from about 10 to 10,000nm.
  16. 제12항에 있어서, 상기 리포좀의 직경이 약 20 내지 500nm임을 특징으로 하는 방법. 13. The method of claim 12, characterized in that the diameter of the liposomes of about 20 to 500nm.
  17. 제12항에 있어서, 상기 약제가 EGF임을 특징으로 하는 방법. 13. The method of claim 12, characterized in that the said medicament EGF.
  18. 리포좀의 흡착의 수단에 의해 눈의 상처 부위에 친밀하게 결합하며, 상기 리포좀은 바라는 치료결과를 성취하기 위하여 충분한 양의 약제를 함유하는 것으로 구성되어지는 눈의 제약 조성물을 눈에 국소적으로 적용 하는 것으로 구성되어 눈의 상처 부위에 약제를 선택적으로 투여하는 방법. And intimately bonded to the wound area of ​​the eye by means of the adsorption of the liposomes, the liposomes are of applying topically a pharmaceutical composition of the eye that is configured to contain a sufficient amount of medicament to the eye in order to achieve the desired therapeutic result It consists in a method of selectively administered the drug to the wound area of ​​the eye.
  19. 재18항에 있어서, 상기 리포좀은 합성 또는 천연적으로 발생하는 인지질 약 50-90몰%및 콜레스테롤 약10~50몰%로 구성되는 것을 특징으로 하는 방법. In the material 18, wherein the liposome is characterized in that it is composed of about 50-90 mole% of a phospholipid that occurs naturally or synthetically and cholesterol about 10 to 50 mol%.
  20. 제19항에 있어서, 상기 인지질은 14 내지 18개의 탄소의 아실 사슬을 가지며, 상기 사슬은 포화되거나 또는 하나의 불포화 결합을 함유하는 포스파티딜콜린, 포스파티글리세롤, 포스타티딜에탄올아민 및 포스파티딜 세린을 구성하는 기로부터 선택된 것임을 특징으로 하는 방법. 20. The method of claim 19 wherein the phospholipid is 14 has a to 18 acyl chain of carbons, wherein the chain is a group of saturated or configure one containing an unsaturated bond phosphatidylcholine, phosphatidic glycerol, poster peptidyl ethanolamine and phosphatidylserine characterized in that from the selected.
  21. 제19항에 있어서, 상기 리포좀은 포스파티딜콜린 50몰%, 포스파티딜글리세롤 30몰% 및 콜레스테롤 20몰%로 구성되는 것을 특징으로 하는 방법. 20. The method of claim 19 wherein the liposome is characterized in that consisting of phosphatidylcholine 50 mol% and 30 mol% phosphatidylglycerol and cholesterol 20 mol%.
  22. 제21항에 있어서, 상기 리포좀의 직경이 약 20내지 500nm임을 특징으로 하는 방법. 22. The method of claim 21, characterized in that the diameter of the liposomes of about 20 to 500nm.
  23. 제18항에 있어서, 상기 리포좀의 직경이 약10 내지 10,000nm임을 특징으로 하는 방법. 19. The method of claim 18, characterized in that the diameter of the liposomes from about 10 to 10,000nm.
  24. 제23항에 있어서, 상기 리포좀의 직경이 약20내지 500nm임을 특징으로 하는 방법. 24. The method of claim 23, characterized in that the diameter of the liposomes of about 20 to 500nm.
  25. 제28항에 있어서, 상기 조성물이 약 5cps와 1000cps사이의 점도를 갖는 조성물 제공하기 위하여 충분한 양의 중합체를 구성하는 것을 특징으로 하는 방법. 30. The method of claim 28, characterized in that the configuration of the sufficient amount of polymer to provide a composition having a viscosity of the composition is between about 5cps and 1000cps.
  26. 제25항에 있어서, 상기 리포좀은 합성 또는 천연적으로 발생하는 인지질 50~90몰% 및 콜레스테롤 10~50몰%으로 구성되고, 상기 중합체 농도가 약 0.25~3.0중량%인 것을 특징으로 하는 방법. 26. The method of claim 25, wherein the liposomes method of synthesis, or consists of a naturally occurring phospholipids from 50 to 90 mol% and cholesterol 10 to 50 mol% occurring, characterized in that the polymer concentration is about 0.25 ~ 3.0 wt%.
  27. 제25항에 있어서, 상기 중합체는 다당류, 겔라틴, 알부민, 카세인, 치토산, 콜라겐, 폴리락티드, 폴리락티드글리코라이드, 코폴리머, 폴리오르소에스터, 폴리메타크릴레이트, 폴리비닐알콜, (폴리아크릴 릭산), 폴리비닐피롤리돈, 폴리하이드록시에틸메타크릴레이트, 폴리에스터아미드, 폴리에틸렌글리콜 및 롤리머릭 아미노산은 구성하는 기로부터 선택되는 것을 특징으로 하는 방법. 26. The method of claim 25, wherein the polymer is a polysaccharide, gelatin, albumin, casein, values ​​acid, collagen, polylactide, polylactide glycolic fluoride, copolymer, poly-ortho ester, polymethacrylate, polyvinyl alcohol, (poly acrylic acid), polyvinyl pyrrolidone, hydroxyethyl methacrylate, polyester, polyamide, polyethylene glycol, and Raleigh numeric amino acids characterized in that the selection from the group constituting.
  28. 제27항에 있어서, 상기 중합체가 겔라틴임을 특징으로 하는 방법. 28. The method of claim 27, characterized in that the polymer is gelatin.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임. ※ Note: will be released by the first application information.
KR1019910701279A 1989-04-04 1990-04-03 Wound, incision, the use of liposomes (liposomes) for the administration of the therapeutic agent to the abrasion site KR920700691A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US33316489A true 1989-04-04 1989-04-04
US333164 1989-04-04
PCT/US1990/001664 WO1990011781A1 (en) 1989-04-04 1990-04-03 The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions

Publications (1)

Publication Number Publication Date
KR920700691A true KR920700691A (en) 1992-08-10

Family

ID=23301595

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701279A KR920700691A (en) 1989-04-04 1990-04-03 Wound, incision, the use of liposomes (liposomes) for the administration of the therapeutic agent to the abrasion site

Country Status (8)

Country Link
EP (1) EP0465588A4 (en)
JP (1) JPH04505319A (en)
KR (1) KR920700691A (en)
AU (1) AU633078B2 (en)
CA (1) CA2013770A1 (en)
IL (1) IL93996D0 (en)
WO (1) WO1990011781A1 (en)
ZA (1) ZA9002593B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012808A1 (en) * 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
IT1240683B (en) * 1990-04-26 1993-12-17 Zambon Spa A pharmaceutical composition containing egf
US5863556A (en) * 1993-08-20 1999-01-26 Euro-Celtique, S.A. Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
DE9312509U1 (en) * 1993-08-20 1993-10-28 Euro Celtique Sa Preparations for external administration of antiseptic and / or wound-healing promoting agents
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
KR100455475B1 (en) * 1996-04-19 2004-12-17 가부시끼 가이샤 알테크 우에노 Drug composition comprising albumin as active ingredient
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
EP0982025A1 (en) * 1998-08-28 2000-03-01 Wilhelm Prof. Dr. Stoffel Synthetic tear fluid
ES2274372T3 (en) 1999-05-27 2007-05-16 Euro-Celtique S.A. Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention or treatment of inflammations inside the human body.
GB9919131D0 (en) * 1999-08-14 1999-10-13 Depuy Int Ltd Joint lubrication
WO2002074281A1 (en) * 2001-03-15 2002-09-26 Novartis Ag Ophthalmic compositions and use thereof
KR100915741B1 (en) * 2001-06-15 2009-09-04 코너스톤 파마슈티칼스 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
DE10141018A1 (en) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Use of negatively charged phospholipids, as well as compositions comprising phospholipids for the treatment of the eye
WO2003024422A1 (en) * 2001-09-18 2003-03-27 Vasogen Ireland Limited Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
HK1077740A1 (en) 2001-12-20 2007-10-12 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
PL371626A1 (en) * 2002-01-21 2005-06-27 Vasogen Ireland Limited Pharmaceutically acceptable phosphate-glycerol carrying bodies
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
WO2004024123A1 (en) * 2002-09-16 2004-03-25 Vasogen Ireland Limited Accelerating recovery from trauma
WO2004037271A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with ps liposomes
AU2003275842A1 (en) * 2002-10-25 2004-05-13 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
WO2004082688A1 (en) * 2003-03-20 2004-09-30 Vasogen Ireland Limited Phosphatidylglycerol (pg) receptor agonists and antagonists
JP4669665B2 (en) * 2004-04-12 2011-04-13 独立行政法人産業技術総合研究所 Polycation-modified liposome having no cytotoxicity and method for producing the same
US8808715B1 (en) * 2004-11-23 2014-08-19 Georgia Regents Research Institute, Inc Methods and compositions for modulating keratinocyte function
US20070071805A1 (en) * 2005-09-26 2007-03-29 Vasogen Ireland Ltd. Treatment of inflammation and vascular abnormalities of the eye
CU23411B6 (en) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Topical epidermal growth factor in liposomes to prevent diabetic foot amputation
CU23388B6 (en) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Pharmaceutical composition of microspheres to prevent amputation of the diabetic foot
ES2284398B2 (en) * 2006-04-27 2008-12-16 Universidad Complutense De Madrid Formulation of liposomal vesicles in water solutions with characteristics of lagrimal film.
KR100752990B1 (en) 2006-08-02 2007-08-22 주식회사 대웅 Compositions for preventing or treating skin diseases comprising nanoliposomes and natural extracts
CA2717133C (en) 2008-02-29 2016-04-26 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
CN102427804A (en) 2009-03-27 2012-04-25 牛津大学之校长及学者 Cholesterol level lowering liposomes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2540381B1 (en) * 1983-02-08 1986-05-30 Dior Sa Parfums Christian Method for stimulating the growth of cells; Cosmetic, pharmaceutical and complementary composition for cell culture medium applying such process
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4692454A (en) * 1986-02-03 1987-09-08 Warner-Lambert Company Opthalmic use of quinolone antibiotics
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
EP0316345A1 (en) * 1986-07-28 1989-05-24 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US5064655A (en) * 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method

Also Published As

Publication number Publication date
ZA9002593B (en) 1991-01-30
WO1990011781A1 (en) 1990-10-18
IL93996D0 (en) 1991-01-31
EP0465588A1 (en) 1992-01-15
AU633078B2 (en) 1993-01-21
AU5429790A (en) 1990-11-05
JPH04505319A (en) 1992-09-17
CA2013770A1 (en) 1990-10-04
EP0465588A4 (en) 1992-06-03

Similar Documents

Publication Publication Date Title
KR920019321A (en) Complex delivery system comprising an adhesive strip and transparent dressing
KR890009355A (en) Women outer protector having a slip-resistant coating
DK0380063T3 (en) 1,2-Cyclohexylaminoarylamider for use as analgesics
DE68919986T2 (en) Preparation of a catheter.
DK0850046T3 (en) Microemulsions for use as vhikel for administration of the active compounds
AT197238T (en) scissors intraocular surgical
KR910006279A (en) 3- (1-substituted-4-piperazinyl) -1h- indazole, their preparation and use as medicament thereof
KR910009240A (en) Transport system of the pharmaceutical or therapeutic agent
FI901648A0 (en) Medicinfoerpackning Foer Komplex therapeutic efficacy behandlingar.
FI920749A0 (en) 1-bifenylmetylimidazolderivat, deras framstaellning Science anvaendning therapeutic efficacy.
FI906367A0 (en) Nukleosider therapeutic efficacy.
AT262920T (en) Continuous low-dose infusion therapy zytokine-
NO892907D0 (en) The wound dressing.
FI893113A (en) Nukleosider therapeutic efficacy.
KR870007703A (en) Device for administration of a medicament suspension
KR910004657A (en) Use as renin inhibitors, their preparation and their pharmaceutical
KR910021399A (en) As a therapeutic agent useful 3-arylcarbonyl indole -1h- and a method of producing
NO2595A (en) Use of a ring system compound for the manufacture of a medicament
NO309705B1 (en) Use of insulin-like growth factor for the manufacture of a medicament for reducing peripheral neuropathy
RU95114405A (en) Application of riluzole as a medicament for the treatment of neurological lesions associated with trauma, and a process for preparing a medicament
NO912397L (en) Polypeptide-polymer conjugate which is active in wound healing.
KR900701346A (en) Transdermal delivery devices are activated line by moisture
KR910004199A (en) The aqueous formulation is a pharmaceutical composition
KR920700003A (en) Prevention and treatment of the novel bacteriocin compositions and methods for use as a microbial infection improved extensively fungicides
DK348588D0 (en) Substituted aromatic sulfonamides for use as anti-glaucoma

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination